참고문헌
- Bekri S, Enica A, Ghafari T, et al. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract 2005;101:c33-c38. https://doi.org/10.1159/000085709
- Rodriguez-Mari A, Coll MJ, Chabas A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat 2003;22:258.
- Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242. https://doi.org/10.1111/j.1365-2362.2004.01309.x
- Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, Aerts JM, Boeschoten EW. alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 2003;18:1581-1584. https://doi.org/10.1093/ndt/gfg194
- Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004;15:1323-1329. https://doi.org/10.1097/01.ASN.0000124671.61963.1E
- Tsakiris D, Simpson HK, Jones EH, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996;11 Suppl 7:4-20. https://doi.org/10.1093/ndt/11.1.4
- Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002;61:249-255. https://doi.org/10.1046/j.1523-1755.2002.00097.x
- Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003;64:801-807. https://doi.org/10.1046/j.1523-1755.2003.00160.x
- Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293. https://doi.org/10.1056/NEJM199508033330504
- Meroni M, Spisni C, Tazzari S, et al. Isolated glomerular proteinuria as the only clinical manifestation of Fabry's disease in an adult male. Nephrol Dial Transplant 1997;12:221-223. https://doi.org/10.1093/ndt/12.1.221
- Brenner BM, Grünfeld JP. Renoprotection by enzyme replacement therapy. Curr Opin Nephrol Hypertens 2004;13:231-241. https://doi.org/10.1097/00041552-200403000-00012
- Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an underrecognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-346. https://doi.org/10.7326/0003-4819-138-4-200302180-00014
- Choi JH, Cho YM, Suh KS, et al. Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease. J Korean Med Sci 2008;23:243-250. https://doi.org/10.3346/jkms.2008.23.2.243
- Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-192. https://doi.org/10.1007/s10545-007-0521-2
- Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004;144(5 Suppl):S20-S26. https://doi.org/10.1016/j.jpeds.2004.01.051
- Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ. Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 2004;50:1979-1985. https://doi.org/10.1373/clinchem.2004.037937
- Ginzburg L, Kacher Y, Futerman AH. The pathogenesis of glycosphingolipid storage disorders. Semin Cell Dev Biol 2004;15:417-431. https://doi.org/10.1016/j.semcdb.2004.03.003
- Pastores GM, Lien YH. Biochemical and molecular genetic basis of Fabry disease. J Am Soc Nephrol 2002;13 Suppl 2:S130-133.
- Nelson BC, Roddy T, Araghi S, et al. Globotriaosylceramide isoform profiles in human plasma by liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004;805:127-134. https://doi.org/10.1016/j.jchromb.2004.02.032
- Mills K, Johnson A, Winchester B. Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett 2002;515:171-176. https://doi.org/10.1016/S0014-5793(02)02491-2
- Young E, Mills K, Morris P, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 2005;94:51-54. https://doi.org/10.1080/08035320510028111
- Yoon HR, Cho K, Yoo HW, et al. Determination of plasma C16- C24 globotriaosylceramide (Gb3) isoforms by tandem mass spectrometry for diagnosis of Fabry disease. J Genet Med 2007;4:45-52.
- Forni S, Fu X, Schiffmann R, Sweetman L. Falsely elevated urinary Gb3(globotriaosylceramide, CTH, GL3). Mol Genet Metab 2009;97:91. https://doi.org/10.1016/j.ymgme.2009.01.011
피인용 문헌
- A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance vol.51, pp.1, 2010, https://doi.org/10.1136/jmedgenet-2013-101857
- Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease vol.52, pp.4, 2010, https://doi.org/10.1136/jmedgenet-2014-102872
- Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype vol.96, pp.29, 2010, https://doi.org/10.1097/md.0000000000007387
- Fabry Nephropathy: An Evidence-Based Narrative Review vol.43, pp.2, 2010, https://doi.org/10.1159/000488121
- Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995-2019 vol.33, pp.3, 2010, https://doi.org/10.1007/s40620-019-00663-6
- Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish co vol.58, pp.10, 2021, https://doi.org/10.1136/jmedgenet-2020-107162
- High-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review vol.11, pp.10, 2021, https://doi.org/10.3390/diagnostics11101779